240 related articles for article (PubMed ID: 36314949)
1. IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2
Xu S; Huang J; Xun Z; Li S; Fu Y; Lin N; Wu W; Chen T; Liu C; Ou Q
Microbiol Spectr; 2022 Dec; 10(6):e0155722. PubMed ID: 36314949
[TBL] [Abstract][Full Text] [Related]
2. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro.
Zhang Q; Wang Y; Wei L; Jiang D; Wang JH; Rao HY; Zhu L; Chen H; Fei R; Cong X
J Gastroenterol Hepatol; 2008 Nov; 23(11):1747-61. PubMed ID: 17559358
[TBL] [Abstract][Full Text] [Related]
3. IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathway.
Lu X; Wang J; Jin X; Huang Y; Zeng W; Zhu J
Biomed Res Int; 2015; 2015():959684. PubMed ID: 25861653
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation.
Mitra B; Wang J; Kim ES; Mao R; Dong M; Liu Y; Zhang J; Guo H
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019054
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells.
Zhang J; Liu K; Zhang G; Ling N; Chen M
Virol J; 2022 Feb; 19(1):28. PubMed ID: 35144643
[TBL] [Abstract][Full Text] [Related]
6. Higher BST2 Expression Promotes the Anti-HBV Effect of IFN-α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg-Positive Chronic Hepatitis B Patients.
Chen J; Hou J; Na R; Zhou B; Hou J; Jiang DK
Clin Pharmacol Ther; 2024 Feb; 115(2):361-370. PubMed ID: 38018367
[TBL] [Abstract][Full Text] [Related]
7. The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy.
Lou S; Wang J; Chen J; Xie H; Chen H; Zhou B; Zhang B; Hou J; Jiang DK
J Infect Dis; 2023 Sep; 228(6):694-703. PubMed ID: 36932045
[TBL] [Abstract][Full Text] [Related]
8. The Study of Immune Response in PBMC of CHB Patients treated with IFN-α and 3-TC in vitro.
Zhang H; Guan ZS; Guan SH; Yang K; Pan Y; Wu YY; Wang AH; Sun BB; Hou J; Mu XX; Gao YF; Cheng WS
Clin Lab; 2016 Dec; 62(12):2313-2318. PubMed ID: 28164560
[TBL] [Abstract][Full Text] [Related]
9. TMEM2 inhibits hepatitis B virus infection in HepG2 and HepG2.2.15 cells by activating the JAK-STAT signaling pathway.
Zhu X; Xie C; Li YM; Huang ZL; Zhao QY; Hu ZX; Wang PP; Gu YR; Gao ZL; Peng L
Cell Death Dis; 2016 Jun; 7(6):e2239. PubMed ID: 27253403
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of a polysaccharide from Radix Isatidis (Isatis indigotica Fortune) against hepatitis B virus (HBV) in vitro via activation of JAK/STAT signal pathway.
Wang T; Wang X; Zhuo Y; Si C; Yang L; Meng L; Zhu B
J Ethnopharmacol; 2020 Jul; 257():112782. PubMed ID: 32217096
[TBL] [Abstract][Full Text] [Related]
11. Silencing SIRT1 promotes the anti-HBV action of IFN-α by regulating Pol expression and activating the JAK-STAT signaling pathway.
Tang Q; Meng C; Liu Y; Cheng Y; Liu Y; Long Y; Sun S; Feng F
Int Immunopharmacol; 2023 Nov; 124(Pt B):110939. PubMed ID: 37741128
[TBL] [Abstract][Full Text] [Related]
12. RIG-I enhances interferon-α response by promoting antiviral protein expression in patients with chronic hepatitis B.
Wu S; Lin J; Fu Y; Ou Q
Antivir Ther; 2018; 23(7):575-583. PubMed ID: 29790851
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha.
Zhao LJ; He SF; Liu Y; Zhao P; Bian ZQ; Qi ZT
Cell Physiol Biochem; 2016; 40(1-2):77-90. PubMed ID: 27855377
[TBL] [Abstract][Full Text] [Related]
14. Suppression of USP18 Potentiates the Anti-HBV Activity of Interferon Alpha in HepG2.2.15 Cells via JAK/STAT Signaling.
Li L; Lei QS; Zhang SJ; Kong LN; Qin B
PLoS One; 2016; 11(5):e0156496. PubMed ID: 27227879
[TBL] [Abstract][Full Text] [Related]
15. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
16. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.
Furutani Y; Toguchi M; Shiozaki-Sato Y; Qin XY; Ebisui E; Higuchi S; Sudoh M; Suzuki H; Takahashi N; Watashi K; Wakita T; Kakeya H; Kojima S
PLoS One; 2019; 14(6):e0216139. PubMed ID: 31188831
[TBL] [Abstract][Full Text] [Related]
17. [The influence of HBV and its antigens on the expressions of JAK-STAT signal transduction pathway molecules and antiviral proteins of IFN alpha].
Guan SH; Yang K; Lu MJ; Lu YP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2011 Jun; 19(6):440-4. PubMed ID: 22053375
[TBL] [Abstract][Full Text] [Related]
18. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
19. The anti-HBV effect mediated by a novel recombinant eukaryotic expression vector for IFN-α.
Yu H; Hou Z; Han Q; Zhang C; Zhang J
Virol J; 2013 Aug; 10():270. PubMed ID: 23984795
[TBL] [Abstract][Full Text] [Related]
20. Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection.
Li Y; Zhu C; Wang F; Zhu T; Li J; Liu S; Xiao F
Mediators Inflamm; 2016; 2016():3894816. PubMed ID: 28077916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
